Logo Image
|Articles|December 10, 2015

An Increasingly Global Approach: January 2016 Therapeutic Innovation & Regulatory Science

Author(s)DIA


DIA Publications Editor-in-Chief Dr. Stephen P. Spielberg previews the upcoming issue of Therapeutic Innovation & Regulatory Science, including articles on clinical trial outcomes, contributions on data quality and central monitoring from TransCelerate BioPharma, and a series of contributions emphasizing the increasingly global nature of medical product development and regulation.

Click here to read the article.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more